Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 8/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3574206 | 0.88 | SCN9A (0.43) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL773872 | 0.82 | PRKCA (0.53) | PRKCAMMP12SCN9ANR1I2KMO | |
| SCHEMBL772130 | 0.82 | PRKCA (0.53) | PRKCAMMP12SCN9ANR1I2KMO | |
| SCHEMBL14253375 | 0.82 | PRKCA (0.55) | PRKCAMMP12SCN9ANR1I2KMO | |
| SCHEMBL4829911 | 0.82 | PRKCA (0.55) | PRKCAMMP12SCN9ANR1I2KMO | |
| SCHEMBL3576706 | 0.81 | PRKCA (0.68) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL3569883 | 0.81 | PRKCA (0.47) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL3574133 | 0.81 | PRKCA (0.47) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL4823428 | 0.80 | SCN9A (0.50) | PRKCAMMP12SCN9ANR1I2KMO | |
| SCHEMBL772511 | 0.80 | PRKCA (0.49) | PRKCAMMP12SCN9ANR1I2KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662809-B2 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2010-02-16 | — | — | US | disclosed |
| US-20080261938-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261938-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, HAVCR2 | PRKCA 4232/4885MMP12 2495/4885SCN9A 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.